Avoid DeliVering TherApies for Non-sustained Arrhythmias in ICD PatiEnts III

NCT ID: NCT00617175

Last Updated: 2025-07-02

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

1902 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-03-31

Study Completion Date

2012-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To demonstrate a reduction in the number of ventricular therapies (ATP and Shocks) delivered for treating spontaneous arrhythmia episodes with a fast cycle length (CL≤ 320ms) as a consequence of self-termination and better arrhythmia discrimination due to a greater number of R-R intervals necessary to detect ventricular events.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary Objective:

The primary objective is to demonstrate a 20% reduction of ventricular therapies (ATP and Shocks) delivered for treating spontaneous arrhythmia episodes with a fast cycle length (CL ≤ 320 ms) by choosing a number of 30 out of 40 intervals to detect (NID) compared to a NID of 18 out of 24 in subjects with either Class I or IIA indication for ICD implantation, regardless of cardiac resynchronization capabilities.

Secondary Objectives:

1. Evaluate the percent reduction in the number of shocks delivered per subject for treating spontaneous episodes with a fast cycle length (CL ≤ 320 ms) and for spontaneous ventricular episodes.
2. Evaluate the efficacy of ATP in successfully treating spontaneous ventricular episodes (CL: 200ms-320ms) for subjects in primary and secondary prevention in both arms of the study.
3. Evaluate acceleration rate or degeneration into VF of spontaneous episodes (CL of 200ms-320ms) due to ATP therapy in the two study arms.
4. Compare the likelihood of syncopal events associated with spontaneous episodes with a fast cycle length (CL ≤ 320 ms).
5. Describe the economic impact and the quality of life consequences.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Long NID

Programming a number of 30 out of 40 intervals to detect (NID)ventricular arrhythmia

Group Type EXPERIMENTAL

Implantable Defibrillator

Intervention Type DEVICE

Number of 30 out of 40 intervals to detect (NID)Fast Ventricular Tachycardia

Short NID

Programming a number of 18 out of 24 intervals to detect (NID)ventricular arrhythmia

Group Type ACTIVE_COMPARATOR

Implantable Defibrillator

Intervention Type DEVICE

number of 18 out of 24 intervals to detect (NID)Fast Ventricular Tachycardia

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Implantable Defibrillator

Number of 30 out of 40 intervals to detect (NID)Fast Ventricular Tachycardia

Intervention Type DEVICE

Implantable Defibrillator

number of 18 out of 24 intervals to detect (NID)Fast Ventricular Tachycardia

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Either ICD or CRT+ICD indications (Class I-IIA) according to the current AHA / ACC / ESC guidelines.
* Previous implant of a Medtronic device including "ATP During Charging" feature for 15 days at the maximum.

Exclusion Criteria

* ICD replacements and upgrading.
* Brugada Syndrome, Long QT and HCM patients
* Ventricular tachyarrhythmia associated with reversible cause.
* Other electrical implantable devices (Neurostimulators, etc.).
* Subject's life expectancy less than 1 year.
* Subject on heart transplant list which is expected in less than 1 year.
* Subject is \<18 years of age, or the subject is under a minimum age that is required as defined by local law
* Women who are pregnant or women of childbearing potential who are not on a reliable form of birth control.
* Unwillingness or inability to provide written informed consent.
* Enrolment in, or intention to participate in, another clinical trial.
* Inaccessibility to come to the study center for the follow-up visits.
* Mechanical tricuspid valve.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medtronic Cardiac Rhythm and Heart Failure

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jorg O. Schwab, MD

Role: STUDY_CHAIR

University of Bonn, Bonn, Germany

Maurizio Gasparini, MD

Role: PRINCIPAL_INVESTIGATOR

Humanitas Hospital, Milano Italy

Maurizio Lunati, MD

Role: PRINCIPAL_INVESTIGATOR

Niguarda Hospital, Milano, Italy

Bernd Lemke, MD

Role: PRINCIPAL_INVESTIGATOR

Klinikum Lüdenscheid, Lüdenscheid, Germany

João Sousa, MD

Role: PRINCIPAL_INVESTIGATOR

H. Santa Maria - Lisbon - Portugal

Andrzej Okreglicki, MD

Role: PRINCIPAL_INVESTIGATOR

University of Cape Town, Cape Town, South Africa

Angel Arenal, MD

Role: PRINCIPAL_INVESTIGATOR

Hospital Gregorio Marañón, Madrid, Spain

Maurits Wijffels, MD

Role: PRINCIPAL_INVESTIGATOR

St. Antonius hospital - NIEUWEGEIN, The Netherlands

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hopital St-Joseph

Gilly, , Belgium

Site Status

CHU Brugmann

Laken, , Belgium

Site Status

CHR La Citadelle Liege

Liège, , Belgium

Site Status

CHR Namur

Namur, , Belgium

Site Status

AZ Nikolaas

Sint-Niklaas, , Belgium

Site Status

KAS Gentofte

Hellerup, , Denmark

Site Status

Odense Universitets Hospital

Odense, , Denmark

Site Status

Turku University Central Hospital

Turku, , Finland

Site Status

Hôpital Michalon- CHU Grenoble

Grenoble, , France

Site Status

CHU Nantes - Hôpital Guillaume et René Laënnec

Nantes, , France

Site Status

NCN Nantes

Nantes, , France

Site Status

Hopital de la Pitie Salpetriere

Paris, , France

Site Status

Centre Hospitalier de Pau

Pau, , France

Site Status

CHU Hôpital de Pontchaillou Rennes

Rennes, , France

Site Status

CH Rangueil Toulouse

Toulouse, , France

Site Status

Clinique Pasteur

Toulouse, , France

Site Status

RWTH Aachen

Aachen, , Germany

Site Status

University of Bonn

Bonn, , Germany

Site Status

Kardiologisches Zentrum an der Klinik Rotes Kreuz

Frankfurt am Main, , Germany

Site Status

SRH Wald-Klinikum Gera gGmbH

Gera, , Germany

Site Status

Universitätskliniken des Saarlandes

Homburg, , Germany

Site Status

Klinikum Lüdenscheid

Lüdenscheid, , Germany

Site Status

Klinikum Dorothea Christiane Erxleben Quedlinburg

Quedlinburg, , Germany

Site Status

Universität Rostock- Medizinische Fakultät

Rostock, , Germany

Site Status

Diakoniekrankenhaus Rotenburg

Rotenburg (Wümme), , Germany

Site Status

Semmelweis University AOK

Budapest, , Hungary

Site Status

Zala County Hospital

Zalaegerszeg, , Hungary

Site Status

Presidio Ospedaliero di Venere

Carbonara, Bari, Italy

Site Status

Azienda.Ospedaliera.G.M. Lancisi

Ancona, , Italy

Site Status

Azienda Ospedaliera G. Rummo

Benevento, , Italy

Site Status

Cliniche Gavazzeni

Bergamo, , Italy

Site Status

Stab. Ospedaliero Di Summa-Perrino - Brindisi

Brindisi, , Italy

Site Status

Casa di Cura Mater Domini

Castellanza, , Italy

Site Status

Ospedale Pugliese e Ciaccio

Catanzaro, , Italy

Site Status

A.O. Santa Croce e Carle

Cuneo, , Italy

Site Status

Ente Ospedaliero Ospedali Galliera - Genova

Genova, , Italy

Site Status

Ospedale Maggiore di Lodi

Lodi, , Italy

Site Status

Istituto Ca' Granda-Niguarda

Milan, , Italy

Site Status

San Carlo Borromeo

Milan, , Italy

Site Status

Nuovo Osp. Civile S. Agostino

Modena, , Italy

Site Status

P.O. di Montebelluna

Montebelluna, , Italy

Site Status

Ospedale S. Giacomo

Novi Ligure, , Italy

Site Status

Policlinico S. Matteo

Pavia, , Italy

Site Status

Osp. S. Maria degli Angeli - Pordenone

Pordenone, , Italy

Site Status

Ospedale Misericordia e Dolce

Prato, , Italy

Site Status

Azienda Complesso Ospedaliero San Filippo Neri

Roma, , Italy

Site Status

Ospedale Sandro Pertini

Roma, , Italy

Site Status

Ospedale Sant Eugenio

Roma, , Italy

Site Status

Istituto Clinico Humanitas

Rozzano, , Italy

Site Status

Osp. S. Giovanni di Dio e Ruggi dAragona

Salerno, , Italy

Site Status

AZ. Osp. Ordine Mauriziano

Torino, , Italy

Site Status

A.O. S.Maria della Misericordia

Udine, , Italy

Site Status

ULSS N.6 S. Bortolo - Vicenza

Vicenza, , Italy

Site Status

Medisch Spectrum Twente

Enschede, , Netherlands

Site Status

St. Antonius Ziekenhuis Nieuwegein

Nieuwegein, , Netherlands

Site Status

Zoz Mswia

Bialystok, , Poland

Site Status

Hospital Garcia Orta, SA

Almada, , Portugal

Site Status

Hospital de Santa Maria

Lisbon, , Portugal

Site Status

Hospital de Santa Marta

Lisbon, , Portugal

Site Status

Hospital Geral de Santo António

Porto, , Portugal

Site Status

Tyumen Cardiology Center

Tyumen, , Russia

Site Status

King Fahd Armed Forces Hospital

Jeddah, , Saudi Arabia

Site Status

King Khalid Univ. Hospital - King Saud University

Riyadh, , Saudi Arabia

Site Status

Bloemfontein Medi-Clinic

Bloemfontein, , South Africa

Site Status

Christiaan Barnard Memorial Hospital

Cape Town, , South Africa

Site Status

University of Cape Town - Groote Schuur Hospital

Cape Town, , South Africa

Site Status

Vincent Pallotti Hospital

Cape Town, , South Africa

Site Status

Milpark Hospital

Johannesburg, , South Africa

Site Status

Sunninghill Hospital

Johannesburg, , South Africa

Site Status

UNITAS Hospital

Pretoria, , South Africa

Site Status

Hospital General Universitario de Alicante

Alicante, , Spain

Site Status

Hospital de Basurto - Bilbao

Bilbao, , Spain

Site Status

Hospital General Yagüe

Burgos, , Spain

Site Status

Hospital General San Pedro de Alcantara

Cáceres, , Spain

Site Status

Hospital General de Ciudad Real

Ciudad Real, , Spain

Site Status

Hospital de Donostia

Donostia / San Sebastian, , Spain

Site Status

Hospital Universitario Virgen de las Nieves

Granada, , Spain

Site Status

H. Ramón y Cajal

Madrid, , Spain

Site Status

Hospital General Universitario Gregorio Marañón

Madrid, , Spain

Site Status

Hospital Puerta de Hierro Majadahonda

Madrid, , Spain

Site Status

Hospital Universitario La Paz

Madrid, , Spain

Site Status

Hospital Clinico de Malaga - Virgen de la Victoria

Málaga, , Spain

Site Status

Hospital Universitario Son Dureta

Palma Mallorca, , Spain

Site Status

Hospital Universitario de San Juan

Sant Joan d'Alacant, , Spain

Site Status

Hospital Ntra. Sra. de la Candelaria

Santa Cruz de Tenerife, , Spain

Site Status

Hospital Universitario de Canarias

Santa Cruz de Tenerife, , Spain

Site Status

Hospital Virgen de La Salud

Toledo, , Spain

Site Status

Hospital Arnau de Vilanova

Valencia, , Spain

Site Status

Hospital Clinico Universitario de Valencia

Valencia, , Spain

Site Status

Chuvi-Xeral-Cíes

Vigo, , Spain

Site Status

Hospital de Txagorritxu

Vitoria-Gasteiz, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium Denmark Finland France Germany Hungary Italy Netherlands Poland Portugal Russia Saudi Arabia South Africa Spain

References

Explore related publications, articles, or registry entries linked to this study.

Landolina M, Boriani G, Biffi M, Cattafi G, Capucci A, Dello Russo A, Facchin D, Rordorf R, Sagone A, Del Greco M, Morani G, Nicolis D, Meloni S, Grammatico A, Gasparini M. Determinants of worse prognosis in patients with cardiac resynchronization therapy defibrillators. Are ventricular arrhythmias an adjunctive risk factor? J Cardiovasc Med (Hagerstown). 2022 Jan 1;23(1):42-48. doi: 10.2459/JCM.0000000000001236.

Reference Type DERIVED
PMID: 34392257 (View on PubMed)

Gasparini M, Kloppe A, Lunati M, Varma N, Martinez-Ferrer JB, Hersi A, Gulaj M, Wijffels MCEF, Arenal A, Mangoni di Santo Stefano L, Proclemer A. Sex differences in implantable cardiac defibrillator therapy according to arrhythmia detection times. Heart. 2020 Apr;106(7):520-526. doi: 10.1136/heartjnl-2019-315650. Epub 2019 Dec 11.

Reference Type DERIVED
PMID: 31826936 (View on PubMed)

Gasparini M, Lunati MG, Proclemer A, Arenal A, Kloppe A, Martinez Ferrer JB, Hersi AS, Gulaj M, Wijffels MCE, Santi E, Manotta L, Varma N. Long Detection Programming in Single-Chamber Defibrillators Reduces Unnecessary Therapies and Mortality: The ADVANCE III Trial. JACC Clin Electrophysiol. 2017 Nov;3(11):1275-1282. doi: 10.1016/j.jacep.2017.05.001. Epub 2017 May 31.

Reference Type DERIVED
PMID: 29759624 (View on PubMed)

Gasparini M, Kloppe A, Lunati M, Anselme F, Landolina M, Martinez-Ferrer JB, Proclemer A, Morani G, Biffi M, Ricci R, Rordorf R, Mangoni L, Manotta L, Grammatico A, Leyva F, Boriani G. Atrioventricular junction ablation in patients with atrial fibrillation treated with cardiac resynchronization therapy: positive impact on ventricular arrhythmias, implantable cardioverter-defibrillator therapies and hospitalizations. Eur J Heart Fail. 2018 Oct;20(10):1472-1481. doi: 10.1002/ejhf.1117. Epub 2017 Dec 18.

Reference Type DERIVED
PMID: 29251799 (View on PubMed)

Kloppe A, Proclemer A, Arenal A, Lunati M, Martinez Ferrer JB, Hersi A, Gulaj M, Wijffels MC, Santi E, Manotta L, Mangoni L, Gasparini M. Efficacy of long detection interval implantable cardioverter-defibrillator settings in secondary prevention population: data from the Avoid Delivering Therapies for Nonsustained Arrhythmias in ICD Patients III (ADVANCE III) trial. Circulation. 2014 Jul 22;130(4):308-14. doi: 10.1161/CIRCULATIONAHA.114.009468. Epub 2014 May 16.

Reference Type DERIVED
PMID: 24838360 (View on PubMed)

Gasparini M, Proclemer A, Klersy C, Kloppe A, Lunati M, Ferrer JB, Hersi A, Gulaj M, Wijfels MC, Santi E, Manotta L, Arenal A. Effect of long-detection interval vs standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial. JAMA. 2013 May 8;309(18):1903-11. doi: 10.1001/jama.2013.4598.

Reference Type DERIVED
PMID: 23652522 (View on PubMed)

Schwab JO, Gasparini M, Lunati M, Proclemer A, Kaup B, Santi E, Ligorio G, Klersy C, DE Sousa J, Okreglicki A, Arenal A, Wijffels M, Lemke B. Avoid delivering therapies for nonsustained fast ventricular tachyarrhythmia in patients with implantable cardioverter/defibrillator: the ADVANCE III Trial. J Cardiovasc Electrophysiol. 2009 Jun;20(6):663-6. doi: 10.1111/j.1540-8167.2008.01415.x. Epub 2009 Jan 9.

Reference Type DERIVED
PMID: 19175450 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ADVANCE III

Identifier Type: -

Identifier Source: secondary_id

ADVANCE III

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The REACT-ICD Trial
NCT02439424 UNKNOWN PHASE1/PHASE2
Cologne Cardioversion Study
NCT02241382 COMPLETED NA